You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IGR-1R

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)

Active, not recruiting
  • Unresectable Intrahepatic Cholangiocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 10, 2023

Advanced or Metastatic Solid Tumors Trial in Toulouse, Villejuif, Barcelona (W0101 - Cohort A1, W0101 - Cohort A2, W0101 -

Active, not recruiting
  • Advanced or Metastatic Solid Tumors
  • W0101 - Cohort A1
  • +2 more
  • Toulouse, France
  • +2 more
Dec 19, 2022

Healthy Women of Child Bearing Potential Trial (R21/Matrix-M1, Saline and R21/Matrix-M1, Sterile isotonic (0.9%) normal saline)

Not yet recruiting
  • Healthy Women of Child Bearing Potential
  • R21/Matrix-M1
  • +2 more
  • (no location specified)
Oct 10, 2023

Solid Tumors, Lymphoma Trial in Worldwide (ASTX660)

Active, not recruiting
  • Solid Tumors
  • Lymphoma
  • Birmingham, Alabama
  • +68 more
Nov 18, 2022

Adrenocortical Carcinoma Trial in Ann Arbor (68Ga-R8760 injection at pre-defined dose levels, 68GA-R8760 injection)

Recruiting
  • Adrenocortical Carcinoma
  • 68Ga-R8760 injection at pre-defined dose levels
  • 68GA-R8760 injection
  • Ann Arbor, Michigan
    University of Michigan Nuclear Medicine
Aug 11, 2023

Cardiovascular Diseases Trial (NVP-2203, NVP-2203-R1, NVP-2203-R2)

Not yet recruiting
  • Cardiovascular Diseases
  • (no location specified)
May 3, 2023

Heart Failure Trial (Bis-Hexanoyl (R)-1,3-Butanediol, Placebo)

Not yet recruiting
  • Heart Failure
  • Bis-Hexanoyl (R)-1,3-Butanediol
  • Placebo
  • (no location specified)
Mar 2, 2023

Healthy Volunteers Trial in Seoul (NVP-1805, NVP-1805-R1 and NVP-1805-R2)

Active, not recruiting
  • Healthy Volunteers
  • Seoul, Korea, Republic of
    H Plus Yangji Hospita
Jan 5, 2023

Neat OGTT, OGTT With Added Sucralose, OGTT With Added Lactisole Trial in New Brunswick (TAS1R2/3 agonist or antagoinst admixture

Completed
  • Neat OGTT
  • +2 more
  • TAS1R2/3 agonist or antagoinst admixture to oral glucose tolerance test
  • New Brunswick, New Jersey
    Rutgers, Department of Nutritional Sciences
Jun 2, 2023

Positron Emission Tomography, Alzheimer, Neurodegenerative Diseases Trial in Shanghai ([18F]CSF-23)

Recruiting
  • Positron Emission Tomography
  • +2 more
  • [18F]CSF-23
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

Role of LncRNA H19 in The Regulation of IGF-1R Expression

Completed
  • Hepatocellular Carcinoma
  • +2 more
  • Blood sample collection
  • Mansoura, Dakahliya, Egypt
  • +1 more
Apr 5, 2022

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma Trial in Barcelona (CD1a-CAR T)

Not yet recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • Lymphoblastic T-Cell Lymphoma
  • CD1a-CAR T
  • Barcelona, Spain
  • +1 more
Jan 10, 2023

Dementia Trial in Oakville, Toronto (Immersive VR Therapy in Head-Mounted Device (HMD))

Not yet recruiting
  • Dementia
  • Immersive VR Therapy in Head-Mounted Device (HMD)
  • Oakville, Ontario, Canada
  • +3 more
May 10, 2023

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)

Terminated
Has Results
  • Rhabdomyosarcoma
  • +2 more
  • Los Angeles, California
  • +1 more
Mar 17, 2022

1-year Mortality in Older r Maintenance Hemodialysis Patients.

Completed
  • Maintenance Hemodialysis
  • Older Patient
    • (no location specified)
    Jan 25, 2023

    Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

    Not yet recruiting
    • Advanced Malignancies
    • 1A46 Drug Substance
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Aug 4, 2023

    Brain Metastases, Brain Metastases, Adult, Brain Cancer Trial in Miami (18F fluciclovine)

    Not yet recruiting
    • Brain Metastases
    • +2 more
    • 18F fluciclovine
    • Miami, Florida
      Miami Cancer Institute
    Sep 15, 2023

    Healthy Trial in Seoul (DA-5218, DA-5218-R1 + DA-5218-R2 + DA-5218-R3)

    Not yet recruiting
    • Healthy
    • DA-5218
    • DA-5218-R1 + DA-5218-R2 + DA-5218-R3
    • Seoul, Korea, Republic of
      Bumin Hospital
    Jul 4, 2022

    Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

    Recruiting
    • Solid Tumor, Adult
    • +6 more
    • TP53-EphA-2-CAR-DC
    • +3 more
    • Beijing, Beijing, China
      Biotherapeutic Department of Chinsese PLA Gereral Hospital
    Nov 29, 2022

    Acute Myeloid Leukemia Trial in Kunming (CLL1 and CD38 dual-target CAR-T injection)

    Recruiting
    • Acute Myeloid Leukemia
    • CLL1 and CD38 dual-target CAR-T injection
    • Kunming, Yunnan, China
      920th Hospital of Joint LogisticsSupport Force of People's Liber
    Oct 26, 2023

    Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

    Recruiting
    • Nasopharyngeal Carcinoma
    • Dalpiciclib Isetionate Tablets, Camrelizumab
    • Guangzhou, Guangdong, China
      Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
    Feb 2, 2023

    Endometrial Cancer Stage I, Endometrial Cancer Stage II Trial in France (ambulatory surgery, standard surgery)

    Completed
    • Endometrial Cancer Stage I
    • Endometrial Cancer Stage II
    • ambulatory surgery
    • standard surgery
    • Clermont-Ferrand, France
    • +8 more
    Dec 10, 2022

    Non-hodgkin Lymphoma, Hodgkin Lymphoma Trial in Valhalla (DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B)

    Recruiting
    • Non-hodgkin Lymphoma
    • Hodgkin Lymphoma
    • DOC Group B
    • +16 more
    • Valhalla, New York
      New York Medical College
    Jun 9, 2022

    Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • Low-Dose Decitabine plus anti-PD-1
    • Beijing, Beijing, China
      ChinaPLAGH
    Apr 18, 2023